Sonoma Pharmaceuticals, Inc. Operating Income Loss

• Sonoma Pharmaceuticals, Inc. showed an increase of +21.1% in Operating Income Loss from 2024 to 2025.
• This data is from Sonoma Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on June 17, 2025.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2011 to 2025), Sonoma Pharmaceuticals, Inc.'s Operating Income Loss has grown by 50.6%.
• Historical annual values: Fiscal year 2025: -$3.71 million | Fiscal year 2024: -$4.70 million | Fiscal year 2023: -$4.57 million | Fiscal year 2022: -$5.89 million | Fiscal year 2021: -$3.45 million | Fiscal year 2020: -$7.39 million | Fiscal year 2019: -$11.26 million | Fiscal year 2018: -$14.19 million | Fiscal year 2017: -$12.97 million | Fiscal year 2016: -$14.71 million | Fiscal year 2015: -$6.66 million | Fiscal year 2014: -$6.05 million | Fiscal year 2013: -$3.37 million | Fiscal year 2012: -$6.47 million | Fiscal year 2011: -$7.51 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026